Dividend Power Score
A single, comprehensive score designed to measure the true strength of a company’s dividend.
This score combines three essential pillars of dividend quality:
Consistency – Measures how reliable the dividend has been over time, focusing on payment history, stability, and the absence of cuts or suspensions.
Payability – Assesses the company’s financial ability to sustain its dividend, taking into account cash flow, earnings coverage, balance sheet strength, and overall financial health.
Growth – Evaluates the long-term growth of both the dividend and the company’s share price, highlighting businesses that consistently increase payouts while creating shareholder value.
Higher scores identify companies that have historically delivered dependable income alongside sustained dividend growth and long-term capital appreciation.
Company Overview
Verrica Pharmaceuticals Inc. is a specialty pharmaceutical company focused on developing and commercializing dermatology therapies for skin diseases with significant unmet medical need. The company operates within the biopharmaceutical and medical dermatology industries, emphasizing conditions where in-office treatments administered by healthcare professionals are standard of care.
The company’s primary revenue driver is YCANTH® (cantharidin topical solution, 0.7%), a proprietary, FDA-approved treatment for molluscum contagiosum, a viral skin infection that primarily affects pediatric patients. Verrica’s strategy centers on leveraging a standardized, pharmaceutical-grade formulation of cantharidin with controlled application, differentiating it from historically compounded, non-FDA-approved alternatives. Verrica Pharmaceuticals was founded in 2013 and completed its initial public offering in 2018, transitioning from a development-stage company to a commercial-stage dermatology-focused biopharmaceutical firm following FDA approval of YCANTH in 2023.
Business Operations
Verrica operates as a single-segment company focused on dermatology therapeutics, with commercial, clinical development, and regulatory activities integrated around its product portfolio. Revenue generation is primarily derived from U.S. sales of YCANTH®, which is marketed to dermatologists and pediatric healthcare providers and administered in clinical settings.
The company’s operations are concentrated in product commercialization, medical affairs, and lifecycle management of cantharidin-based therapies. Verrica controls proprietary drug-device combination technology related to precise topical application. Manufacturing is conducted through third-party contract manufacturers, and the company relies on specialized distribution partners for U.S. commercial supply. As of publicly available disclosures, Verrica does not report material joint ventures or revenue-generating subsidiaries beyond its core corporate structure.
Strategic Position & Investments
Strategically, Verrica is focused on expanding adoption of YCANTH® in the U.S. market and pursuing label expansion opportunities for additional dermatologic indications where cantharidin has historical clinical use. Growth initiatives have included investment in commercial infrastructure, payer access, and post-marketing clinical studies to support broader utilization.
Verrica has historically invested in clinical-stage assets targeting additional skin conditions, including common warts, though development timelines and outcomes have varied. The company has not completed large-scale acquisitions but has relied on internal development and licensing of formulation and delivery technologies. Its strategic positioning emphasizes first-mover advantage as the only FDA-approved cantharidin product, creating regulatory and competitive barriers in a niche but established treatment category.
Geographic Footprint
Verrica Pharmaceuticals is headquartered in the United States, with its principal executive offices located in Pennsylvania. The company’s commercial operations are currently focused on the U.S. market, which represents its primary source of revenue and regulatory approval.
Internationally, Verrica has limited direct operational presence. Any ex-U.S. strategy has been described as opportunistic and dependent on regulatory pathways and potential partnerships, rather than through owned infrastructure. As of the latest public disclosures, the company does not report material commercial sales or physical operations outside the United States.
Leadership & Governance
Verrica is led by an executive team with experience in dermatology, specialty pharmaceuticals, and commercial-stage biotech operations. The leadership has emphasized disciplined commercialization, regulatory compliance, and focused capital allocation as part of its governance and operating philosophy.
Key executives include:
- Ted White – President and Chief Executive Officer
- Robyn F. Webster – Chief Financial Officer
- David J. Mazzo, Ph.D. – Chief Development Officer
- Michelle Stewart – Chief Commercial Officer
The company is governed by a board of directors with backgrounds in biopharmaceutical development, public company oversight, and healthcare investing, aligning governance priorities with shareholder accountability and long-term value creation.